Aberrant regulation of the GSK ‐3β/ NRF 2 axis unveils a novel therapy for adrenoleukodystrophy
Open accessThe DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
The nuclear factor erythroid 2‐like 2 (NRF2) is the master regulator of endogenous antioxidant responses. Oxidative damage is a shared and early‐appearing feature in X‐linked adrenoleukodystrophy (X‐ALD) patients and the mouse model (Abcd1 null mouse). This rare neurometabolic disease is caused by the loss of function of the peroxisomal transporter ABCD1, leading to an accumulation of very long‐chain fatty acids and the induction of reactive oxygen species of mitochondrial origin. Here, we identify an impaired NRF2 response caused by aberrant activity of GSK‐3β. We find that GSK‐3β inhibitors can significantly reactivate the blunted NRF2 response in patients’ fibroblasts. In the mouse models (Abcd1− and Abcd1−/Abcd2−/− mice), oral administration of dimethyl fumarate (DMF/BG12/Tecfidera), an NRF2 activator in use for multiple sclerosis, normalized (i) mitochondrial depletion, (ii) bioenergetic failure, (iii) oxidative damage, and (iv) inflammation, highlighting an intricate cross‐talk governing energetic and redox homeostasis in X‐ALD. Importantly, DMF halted axonal degeneration and locomotor disability suggesting that therapies activating NRF2 hold therapeutic potential for X‐ALD and other axonopathies with impaired GSK‐3β/NRF2 axis. This study reports an aberrant, chronic inhibition of the endogenous antioxidant response driven by NRF2 in adrenoleukodystrophy. Reactivating this pathway in the mouse model with dimethyl fumarate unveils a promising therapeutic option. This study reports an aberrant, chronic inhibition of the endogenous antioxidant response driven by NRF2 in adrenoleukodystrophy. Reactivating this pathway in the mouse model with dimethyl fumarate unveils a promising therapeutic option.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hematopoietic Stem Cell Gene Therapy with a Lentiviral Vector in X-Linked Adrenoleukodystrophy
Cartier, N., Hacein-Bey-Abina, S., Bartholomae, C. C., Veres, G., Schmidt, M., Kutschera, I., Vidaud, M., Abel, U., Dal-Cortivo, L., Caccavelli, L., et al. (2009) · Science · doi:10.1126/science.1171242 · Cited by 1,508 · cited 1×
“Current therapeutic options are restricted to bone marrow transplantation (Miller et al, 2011) and hematopoietic stem cell gene therapy (Cartier et al, 2009; Eichler et al, 2017), and are limited by a very narrow therapeutic window, which reinforces the need to develop additional therapies for this…”
Putative X-linked adrenoleukodystrophy gene shares unexpected homology with ABC transporters
Mosser, J., Douar, A.-M., Sarde, C.-O., Kioschis, P., Feil, R., Moser, H., Poustka, A.-M., Mandel, J.-L., & Aubourg, P. (1993) · Nature · doi:10.1038/361726a0 · Cited by 1,202 · cited 1×
“It is caused by mutations in the ABCD1 gene (Mosser et al, 1993) located on 1 Neurometabolic Diseases Laboratory, Bellvitge Biomedical Research Institute (IDIBELL), L’Hospitalet de Llobregat, Barcelona, Spain 2 CIBERER U759, Center for Biomedical Research on Rare Diseases, ISCIII, Barcelona, Spain…”
Linker, R. A., Lee, D.-H., Ryan, S., van Dam, A. M., Conrad, R., Bista, P., Zeng, W., Hronowsky, X., Buko, A., Chollate, S., et al. (2011) · Brain · doi:10.1093/brain/awq386 · Cited by 1,155 · cited 4×
“…depletion, bioenergetic failure, and oxidative damage in Abcd1 mice To elucidate the impact of a defective NRF2-dependent response in the pathogenesis of adrenoleukodystrophy, we decided to treat Abcd1 mice with DMF, a classical activator of NRF2 (Linker et al, 2011; Scannevin et al, 2012).”
InfluentialExpression of Nrf2 in Neurodegenerative Diseases
Ramsey, C. P., Glass, C. A., Montgomery, M. B., Lindl, K. A., Ritson, G. P., Chia, L. A., Hamilton, R. L., Chu, C. T., & Jordan-Sciutto, K. L. (2007) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/nen.0b013e31802d6da9 · Cited by 760
Rada, P., Rojo, A. I., Chowdhry, S., McMahon, M., Hayes, J. D., & Cuadrado, A. (2011) · Molecular and Cellular Biology · doi:10.1128/mcb.01204-10 · Cited by 759 · cited 1×
“Several signals can regulate NRF2-dependent responses, in particular those that modulate GSK-3b activity (Salazar et al, 2006; Rojo et al, 2008; Rada et al, 2011).”
Hematopoietic stem-cell gene therapy for cerebral adrenoleukodystrophy
Eichler, F., Duncan, C., Musolino, P. L., Orchard, P. J., De Oliveira, S., Thrasher, A. J., Armant, M., Dansereau, C., Lund, T. C., Miller, W. P., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1700554 · Cited by 604 · cited 1×
“…options are restricted to bone marrow transplantation (Miller et al, 2011) and hematopoietic stem cell gene therapy (Cartier et al, 2009; Eichler et al, 2017), and are limited by a very narrow therapeutic window, which reinforces the need to develop additional therapies for this…”
Chen, P.-C., Vargas, M. R., Pani, A. K., Smeyne, R. J., Johnson, D. A., Kan, Y. W., & Johnson, J. A. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0813361106 · Cited by 579
Engelen, M., Kemp, S., de Visser, M., van Geel, B. M., Wanders, R. J., Aubourg, P., & Poll-The, B. (2012) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-7-51 · Cited by 562
A Phase II Trial of Tideglusib in Alzheimer's Disease
Lovestone, S., for the ARGO investigators, Boada, M., Dubois, B., Hüll, M., Rinne, J. O., Huppertz, H.-J., Calero, M., Andrés, M. V., Gómez-Carrillo, B., et al. (2015) · Journal of Alzheimer's Disease · doi:10.3233/jad-141959 · Cited by 536 · cited 1×
“Two phase II clinical trials with the GSK-3b inhibitor, Tideglusib, showed no clinical benefits in Alzheimer’s disease (Lovestone et al, 2015) and progressive supranuclear palsy (Tolosa et al, 2014).”
Ring, D. B., Johnson, K. W., Henriksen, E. J., Nuss, J. M., Goff, D., Kinnick, T. R., Ma, S. T., Reeder, J. W., Samuels, I., Slabiak, T., et al. (2003) · Diabetes · doi:10.2337/diabetes.52.3.588 · Cited by 532 · cited 1×
“For this, we assessed whether specific GSK-3b inhibitors (CT99021 and SB216763; Coghlan et al, 2000; Ring et al, 2003) could restore a normal NRF2-dependent response in X-ALD fibroblasts.”
GSK-3β, a pivotal kinase in Alzheimer disease
Llorens-MarÃtin, M., Jurado, J., Hernández, F., & Ãvila, J. (2014) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2014.00046 · Cited by 451
A phase 2 trial of the GSK‐3 inhibitor tideglusib in progressive supranuclear palsy
Tolosa, E., Litvan, I., Höglinger, G. U., Burn, D., Lees, A., Andrés, M. V., Gómez‐Carrillo, B., León, T., del Ser, T., & for the TAUROS Investigators (2014) · Movement Disorders · doi:10.1002/mds.25824 · Cited by 320 · cited 1×
“Two phase II clinical trials with the GSK-3b inhibitor, Tideglusib, showed no clinical benefits in Alzheimer’s disease (Lovestone et al, 2015) and progressive supranuclear palsy (Tolosa et al, 2014).”
Miller, W. P., Rothman, S. M., Nascene, D., Kivisto, T., DeFor, T. E., Ziegler, R. S., Eisengart, J., Leiser, K., Raymond, G., Lund, T. C., et al. (2011) · Blood · doi:10.1182/blood-2011-01-329235 · Cited by 290
Shih, A. Y., Imbeault, S., Barakauskas, V., Erb, H., Jiang, L., Li, P., & Murphy, T. H. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m414635200 · Cited by 273 · cited 1×
“Ex vivo studies and analysis of neurodegenerative models for motor neuron disorders, Parkinson’s disease, or cerebral ischemia indicate that NRF2-mediated neuroprotection critically involves astrocyte-induced effects (Kraft et al, 2004; Shih et al, 2005; Chen et al, 2009).”
Calkins, M. J., Jakel, R. J., Johnson, D. A., Chan, K., Kan, Y. W., & Johnson, J. A. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0408487101 · Cited by 247
X-linked adrenoleukodystrophy in women: A cross-sectional cohort study
Engelen, M., Barbier, M., Dijkstra, I. M. E., Schür, R., de Bie, R. M. A., Verhamme, C., Dijkgraaf, M. G. W., Aubourg, P. A., Wanders, R. J. A., van Geel, B. M., et al. (2014) · Brain · doi:10.1093/brain/awt361 · Cited by 234
The human peroxisomal ABC half transporter ALDP functions as a homodimer and accepts acyl–CoA esters
van Roermund, C. W. T., Visser, W. F., IJlst, L., van Cruchten, A., Boek, M., Kulik, W., Waterham, H. R., & Wanders, R. J. A. (2008) · The FASEB Journal · doi:10.1096/fj.08-110866 · Cited by 233 · cited 1×
“Published under the terms of the CC BY 4.0 license EMBO Molecular Medicine 10: e8604 | 2018 1 of 16 Xq.28, which encodes a peroxisomal transporter that moves very long-chain fatty acids (VCLFA) into the peroxisome for degradation by b-oxidation (van Roermund et al, 2008; Wiesinger et al, 2013).”
InfluentialPujol, A. (2002) · Human Molecular Genetics · doi:10.1093/hmg/11.5.499 · Cited by 214
Self-citationEarly oxidative damage underlying neurodegeneration in X-adrenoleukodystrophy
Fourcade, S., Lopez-Erauskin, J., Galino, J., Duval, C., Naudi, A., Jove, M., Kemp, S., Villarroya, F., Ferrer, I., Pamplona, R., et al. (2008) · Human Molecular Genetics · doi:10.1093/hmg/ddn085 · Cited by 214 · cited 12×
“AASA, CML, CEL, and MDAL concentrations in total proteins from spinal cord homogenates were measured by gas chromatography/ ª 2018 The Authors EMBO Molecular Medicine 10: e8604 | 2018 11 of 16 mass spectrometry (GC/MS), as reported (Fourcade et al, 2008).”
InfluentialSelf-citationPujol, A., Ferrer, I., Camps, C., Metzger, E., Hindelang, C., Callizot, N., Ruiz, M., Pàmpols, T., Giròs, M., & Mandel, J. L. (2004) · Human Molecular Genetics · doi:10.1093/hmg/ddh323 · Cited by 201 · cited 4×
“…we assessed the clinical signs of adrenomyeloneuropathy in Abcd1 /Abcd2 / (DKO) mice, which display increased VLCFA accumulation in the spinal cord (Pujol et al, 2004), higher levels of oxidative damage to proteins (Fourcade et al, 2008; Galino et al, 2011), and a more severe…”
InfluentialSelf-citationHein, S., Schonfeld, P., Kahlert, S., & Reiser, G. (2008) · Human Molecular Genetics · doi:10.1093/hmg/ddn066 · Cited by 180 · cited 1×
“…VLCFA-induced oxidative stress is a critical, early pathogenic factor in X-ALD (Vargas et al, 2004; Powers et al, 2005; Fourcade et al, 2008, 2010; Hein et al, 2008; LopezErauskin et al, 2011; Petrillo et al, 2013), although the exact mechanisms by which VLCFA-induced redox imbalance causes…”
Wiesinger, C., Kunze, M., Regelsberger, G., Forss-Petter, S., & Berger, J. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.445445 · Cited by 145
Berger, J., Molzer, B., Fae, I., & Bernheimer, H. (1994) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1994.2855 · Cited by 126
López-Erauskin, J., Galino, J., Ruiz, M., Cuezva, J. M., Fabregat, I., Cacabelos, D., Boada, J., Martínez, J., Ferrer, I., Pamplona, R., et al. (2013) · Human Molecular Genetics · doi:10.1093/hmg/ddt186 · Cited by 125 · cited 2×
“Both compounds produce mitochondrial ROS in these fibroblasts (Lopez-Erauskin et al, 2013).”
Self-citationKemper, A. R., Brosco, J., Comeau, A. M., Green, N. S., Grosse, S. D., Jones, E., Kwon, J. M., Lam, W. K. K., Ojodu, J., Prosser, L. A., et al. (2017) · Genetics in Medicine · doi:10.1038/gim.2016.68 · Cited by 109
A key role for the peroxisomal ABCD2 transporter in fatty acid homeostasis
Fourcade, S., Ruiz, M., Camps, C., Schlüter, A., Houten, S. M., Mooyer, P. A. W., Pàmpols, T., Dacremont, G., Wanders, R. J. A., Giròs, M., et al. (2009) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.90736.2008 · Cited by 104 · cited 1×
“The closest homolog Abcd2 exhibits overlapping metabolic functions (Fourcade et al, 2009) and has been postulated as modifier of the biochemical defect (Muneer et al, 2014).”
Self-citationWang, Q., Li, W.-X., Dai, S.-X., Guo, Y.-C., Han, F.-F., Zheng, J.-J., Li, G.-H., & Huang, J.-F. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-161032 · Cited by 88 · cited 1×
“A recent meta-analysis identified the NRF2 pathway as a common dysregulated hub in Alzheimer’s and Parkinson’s disease patients (Wang et al, 2017).”
Functional genomic analysis unravels a metabolic-inflammatory interplay in adrenoleukodystrophy
Schlüter, A., Espinosa, L., Fourcade, S., Galino, J., López, E., Ilieva, E., Morató, L., Asheuer, M., Cook, T., McLaren, A., et al. (2012) · Human Molecular Genetics · doi:10.1093/hmg/ddr536 · Cited by 72
Self-citationMuneer, Z., Wiesinger, C., Voigtländer, T., Werner, H. B., Berger, J., & Forss-Petter, S. (2014) · PLoS ONE · doi:10.1371/journal.pone.0108655 · Cited by 33 · cited 1×
“The closest homolog Abcd2 exhibits overlapping metabolic functions (Fourcade et al, 2009) and has been postulated as modifier of the biochemical defect (Muneer et al, 2014).”
Cited by
Deciphering the modifiers for phenotypic variability of X-linked adrenoleukodystrophy
Palakuzhiyil, S. V., Christopher, R., & Chandra, S. R. (2020) · World Journal of Biological Chemistry · doi:10.4331/wjbc.v11.i3.99 · Cited by 24
Coppa, A., Guha, S., Fourcade, S., Parameswaran, J., Ruiz, M., Moser, A. B., Schlüter, A., Murphy, M. P., Lizcano, J. M., Miranda-Vizuete, A., et al. (2020) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2020.01.177 · Cited by 23
Self-citationPathophysiology of X-Linked Adrenoleukodystrophy: Updates on Molecular Mechanisms
Parasar, P., Kaur, N., & Singh, J. (2024) · Journal of Biotechnology and Biomedicine · doi:10.26502/jbb.2642-91280151 · Cited by 12
“Defective phosphorylation of AKT resulted in the activation of GSK-3β which further represses NRF2 [52].”
Ataxia with giant axonopathy in Acbd5 -deficient mice halted by adeno-associated virus gene therapy
Granadeiro, L., Zarralanga, V. E., Rosa, R., Franquinho, F., Lamas, S., & Brites, P. (2024) · Brain · doi:10.1093/brain/awad407 · Cited by 9
Kaur, N., & Singh, J. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26041576 · Cited by 4
Metadata
- Authors
- Ranea‐Robles, P., Launay, N., Ruiz, M., Calingasan, N. Y., Dumont, M., Naudí, A., Portero‐Otín, M., Pamplona, R., Ferrer, I., Beal, M. F., Fourcade, S., & Pujol, A.
- Venue
- EMBO Molecular Medicine
- Published
- 2018-07-11
- Volume
- 10
- Issue
- 8
- ISSN
- 1757-4676 (ISSN-L)
- 1757-4684
- OpenAlex
- W2861844602
- Cited by
- 55
- References
- 29
- FWCI
- 3.90
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.